傲農生物(603363.SH):“詔安優農10000頭商品母豬場項目”延期
格隆匯 3 月 17日丨傲農生物(603363.SH)公佈,公司於2021年3月17日召開公司第二屆董事會第四十四次會議,審議通過了《關於部分募集資金投資項目延期的議案》,擬將公司非公開發行股票募集資金投資項目中的“詔安優農10000頭商品母豬場項目”進行延期。
該項目原計劃於2021年3月建成投產,因前期公司配合當地政府要求對項目建設的外省施工人員實行階段引進,以及受外部環境影響設備廠家未能按原計劃將設備送達,導致項目工期有所延後,目前項目主體土建施工已經完成,在進行外圍附屬設施收尾工作,設備安裝在全面加緊施工中,該項目預計於2021年5月投產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.